434 related articles for article (PubMed ID: 32045874)
21. Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center.
Wehner T; Mannan S; Turaga S; Vallabhaneni K; Yip HM; Wiggans C; Shankar R; Duncan JS; Sander JW
Epilepsy Behav; 2017 Aug; 73():106-110. PubMed ID: 28624720
[TBL] [Abstract][Full Text] [Related]
22. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience.
Juhl S; Rubboli G
Acta Neurol Scand; 2016 Nov; 134(5):374-377. PubMed ID: 26763771
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center.
Kurth C; Kockelmann E; Steinhoff BJ
Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
26. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and tolerability of adjunctive brivaracetam for the treatment of adult epilepsy: An Australian multi-center retrospective real-world observational cohort study.
Halliday AJ; Vogrin S; Ignatiadis S; Gillinder L; Jones D; Kiley M; Kwan P; Seneviratne U; Somerville E; Whitham E;
Epilepsy Behav; 2023 Aug; 145():109287. PubMed ID: 37336131
[TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
[TBL] [Abstract][Full Text] [Related]
29. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
Santamarina E; Bertol V; Garayoa V; García-Gomara MJ; Garamendi-Ruiz I; Giner P; Aranzábal I; Piera A; Arcos C; Esteve P; Marinas A; García-Escrivá A; Viloria-Alebesque A; Loro FA; de Tienda AP; Olivan JA; Bonet M; Dávila-González P; Sivera R; Molins A; Sansa G; Roche JC; Martínez AB; Monteagudo S; Casadevall T
Seizure; 2020 Dec; 83():48-56. PubMed ID: 33096456
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy.
Pascarella A; Iannone LF; Di Gennaro G; D'Aniello A; Ferlazzo E; Gagliostro N; Ursini F; Bonanni P; Paciello N; Romigi A; Aguglia U; De Sarro G; Russo E; Gambardella A; Labate A
J Neurol Sci; 2020 Aug; 415():116903. PubMed ID: 32447055
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
33. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
[TBL] [Abstract][Full Text] [Related]
34. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
[TBL] [Abstract][Full Text] [Related]
35. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures.
Chung SS; Hogan RE; Blatt I; Lawson P B; Nguyen H; Clark AM; Anders B; Halvorsen MB;
Epilepsy Behav; 2016 Jun; 59():13-20. PubMed ID: 27084978
[TBL] [Abstract][Full Text] [Related]
37. Effect of perampanel on aggression in patients with refractory focal epilepsy: A 6-month longitudinal study.
Lee SA; Jeon JY; Kim HW
Epilepsy Behav; 2020 Jan; 102():106658. PubMed ID: 31743838
[TBL] [Abstract][Full Text] [Related]
38. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
[TBL] [Abstract][Full Text] [Related]
40. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
